Home » Stocks » DYN

Dyne Therapeutics, Inc. (DYN)

Stock Price: $17.47 USD 0.49 (2.89%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 894.57M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 51.21M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $17.47
Previous Close $16.98
Change ($) 0.49
Change (%) 2.89%
Day's Open 17.25
Day's Range 17.03 - 17.91
Day's Volume 143,767
52-Week Range 13.50 - 32.31


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating sustained knockdown of toxic human nuclear DMPK R...

1 day ago - Benzinga

- Robust Reduction in DMPK RNA in Multiple Muscles at Four Weeks in Novel In Vivo Model Developed by Dyne; Additional In Vitro Data Support Advancement of Lead DM1 Candidate -

1 day ago - GlobeNewsWire

- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 -

1 week ago - GlobeNewsWire

Company to host webcast including leading DM1 expert, Dr. Charles Thornton, following presentations on May 14, 2021 Company to host webcast including leading DM1 expert, Dr. Charles Thornton, following ...

2 weeks ago - GlobeNewsWire

- Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4'21 and Q4'22 -

2 months ago - GlobeNewsWire

Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease

2 months ago - GlobeNewsWire

Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease

3 months ago - GlobeNewsWire

WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ge...

3 months ago - GlobeNewsWire

- In Vivo Model Developed by Dyne Sets New Standard for Evaluating  Pharmacodynamics in DM1 -

4 months ago - GlobeNewsWire

About DYN

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.

Pharmaceutical Preparation Manufacturing
IPO Date
Sep 17, 2020
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DYN stock is "Buy." The 12-month stock price forecast is 38.75, which is an increase of 121.81% from the latest price.

Price Target
(121.81% upside)
Analyst Consensus: Buy